Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache

CONCLUSIONS: Across 24 weeks of treatment, eptinezumab reduced AHM use in patients diagnosed with CM and MOH. More than one-fourth (29%) of patients treated with eptinezumab did not meet the diagnostic thresholds for either CM or MOH for the entire treatment period.PMID:34551130 | DOI:10.1111/head.14206

Source: Headache - September 22, 2021 Category: Neurology Authors: Michael J Marmura Hans-Christoph Diener Robert P Cowan Stewart J Tepper Merle L Diamond Amaal J Starling Joe Hirman Lahar Mehta Thomas Brevig Roger Cady Source Type: research